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Abstract 
Mildly elevated serum unconjugated bilirubin (UCB) concentrations are associated with protection 
against disease conditions underpinned by cellular and metabolic stress. To determine the potential 
therapeutic efficacy of UCB we tested it in an in vitro model of gut inflammation. Tunicamycin TUN 
(10 µg/mL) was used to induce endoplasmic reticular stress (ERS) affecting N-glycosylation in 
LS174T cells. Cultured cells were investigated with addition of UCB at doses 0.1, 1 and 10µM 
(resulting in bilirubin:albumin ratios of 0.325–0.003)against ER stress-mediated effects including 
inflammation, cell survival (determined by apoptosis) and proliferation. Gene expression of ER 
stress markers (Grp78, Perk, XBP1 and ATF6) were evaluated in addition to cytokine 
concentrations in media after six hours of treatment. We then verified the potential role of UCB in 
executing programmed cell death via PARP, Caspase3 and Annexin V assays and further explored 
cell proliferation using the Click-iT EdU assay. A dose of 10µM UCB most potently reduced 
tunicamycin-mediated effects on enhanced UPR markers, inflammatory cytokines and proliferation; 
however all the doses (i.e.0.1–10µM) reduced the expression of ER stress and inflammatory 
markers Grp78, NLRP3, IL1-b, XBP1, PERK and ATF6. Furthermore, media concentrations of 
pro-inflammatory cytokines IL-8, IL-4 and TNFα decreased and the anti-inflammatory cytokine IL-10 
increased (P<0.05). A dose of 10µM UCB initiated intrinsic apoptosis via Caspase 3 and in addition 
reduced cellular proliferation. Collectively, these data indicate that co treatment with UCB resulted 
in reducing ER stress response to TUN in gastrointestinal epithelial cells, reduced the subsequent 
inflammatory response, induced cancer cell death and decreased cellular proliferation. These data 
suggest that mildly elevated circulating or enteric UCB might protect against gastrointestinal 
inflammatory disorders. 
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Introduction 
The prime function of ER stress is to activate 
specific enzymes and transcription factors in order to 
maintain homeostasis within the endoplasmic 
reticulum (ER). However, initiation of inflammatory 
signalling or conditions typified by increased 
programmed cell death (apoptosis) occurs if ER stress 
becomes chronic [1]. Disturbances in ER function 
trigger the unfolded protein response (UPR), a tightly 
orchestrated collection of intracellular signal 
transduction reactions designed to restore protein 
homeostasis. A critical initiator of the UPR is Grp78. 
Grp78 binds to three major molecules, namely IRE1α, 
PERK and ATF6. IRE1α-mediated signalling orchestr-
ates cell-fate decisions during stress, i.e. it signals the 
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intensity of cellular stress thereby clearly showing 
that ER stress has a role in cell survival [2]. 
Translation of proteins occurs in the ER and there is 
increased protein folding and transport during 
conditions such as carcinogenesis. The ER stress 
response, which is cytoprotective, is involved in 
supporting tumour growth and adaptation [3]. 
Cancerous cells adapt to prevent ER stress-mediated 
apoptosis in order to survive by expression of 
inhibition of apoptosis (IAP) proteins [4]. Novel 
therapeutics against ER stress are required in order to 
arrest cancer growth by increasing apoptosis and 
decreasing cellular proliferation. Some initial targets 
included inhibition of reactive oxygen species (ROS) 
generation and reducing ER stress [5]. Cells deficient 
in PERK have comparatively less ROS compared to 
those with PERK, demonstrating that loss of PERK 
has an impact on ROS-induced ER stress, leading to 
apoptosis. Oxidative stress in this scenario directed 
PERK-mediated ER stress signaling [5]. Antioxidants, 
including polyphenols, induce cancer cell death via 
various pathways including NF-kB/p53, suppression 
of MMP-2 expression, ERK and c-Jun N-terminal 
kinase (JNK). They can also target angiogenesis- 
related pathways including PI3K/Akt/Fork head box 
O (FoxO) [6]. As ROS inhibition influences ER stress 
pathways, PERK, which is one of the regulators of the 
growth of cancer cells, was chosen as a target. PERK 
inhibition via DNA damage checkpoint prevented 
mammary carcinoma cells from forming solid 
tumours in vivo, denoting its role in tumour initiation 
and redox homeostasis [3], and suggesting that 
compounds with antioxidant capacity might 
represent effective treatments to prevent ER stress 
and cellular proliferation. Benzodiazepines [7] were 
used to attenuate ER stress via Grp78 reduction in 
neural stem cells. Kifunensine mannosidase inhibitors 
[8, 9] were employed to decrease the ER stress via 
impeding CHOP expression in cervical cancer cells. 
Stocker and colleagues demonstrated that the 
endogenous heme catabolite unconjugated bilirubin 
(UCB) exhibited potent antioxidant effects and 
inhibited lipid oxidation in vitro [10, 11]. UCB also 
scavenges oxidants (i.e. hydrogen peroxide and other 
peroxides) and multiple radical species [12] demonst-
rating broad specificity in its ROS-neutralising effects 
[13]. Bilirubin’s antioxidant capacity and ability to 
inhibit lipid peroxidation are supported in vivo, with 
serum bilirubin positively correlating with total anti- 
oxidant capacity in plasma [14, 15] and negatively 
correlating with susceptibility to copper induced lipid 
oxidation [16]. 
Endogenously elevated UCB is also associated 
with protection from circulating oxidative stress in an 
animal model of adenine-induced renal failure [17]. 
Biliveridin (BV), which is chemically reduced to 
bilirubin in vivo, also protects against vascular injury, 
ischemia reperfusion injury [18] and inhibits Toll-like 
receptor4 (TLR4) activation in mouse macrophages 
[19, 20]. BV also ameliorates complement-mediated 
inflammation and reduces pro-inflammatory cytokine 
expression including TNF-α and IL-6 [19]. A strong 
evidence suggests that mild hyperbilirubinemia may 
exhibit protection against diabetic vascular 
complications and also impede oxidative stress [21]. A 
study by Barateiro et al., has demonstrated the 
interrelation between UCB and ERS and associated 
cascade of events [22]. Despite these findings which 
describe antioxidant and anti-inflammatory effects, 
very little is known regarding bilirubin’s impact on 
gut health. Therefore, we aimed to determine whether 
bilirubin, which is produced during stress conditions 
and possesses antioxidant activity, might prevent ER 
stress, inhibit inflammatory responses and encourage 
apoptosis in LS174T cells. 
Materials and Methods  
Unconjugated bilirubin 
UCB was obtained from Frontier Scientific (Utah, 
USA) and was added to media without further 
purification. All UCB solutions were protected from 
light using foil and replaced daily in cell culture. UCB 
was dissolved in 0.1% DMSO. UCB is carried by 
albumin with the bilirubin: albumin concentration 
dictating its toxicity in vivo. Therefore, we aimed to 
test UCBs efficacy at bilirubin to albumin ratios of 
<0.5.  
The concentration of albumin in FBS was 
calculated using an album in specific kit (ALB2) and a 
Cobas Integra 400+ clinical chemistry analyzer (Roche 
Diagnostics, North Ryde, NSW, Australia). Given that 
the FBS concentration in media was 10%v/v, FBS 
albumin concentrations were divided by 10 to obtain 
the bilirubin: albumin ratio in culture. To achieve this, 
the albumin concentration was converted to a molar 
concentration, assuming a molecular mass for 
albumin of 66.5 kDa. The albumin concentration in 
FBS equaled 20.5 g/L (308 µM), and therefore equaled 
30.8 µM in media. This resulted in bilirubin: albumin 
ratios of 0.325, 0.032 and 0.003 for 10,1 and 0.1 µM 
UCB concentrations in media. 
Cell culture 
Human colorectal adenocarcinoma cells LS174T 
(ATCC) were  cultured in RPMI (1640medium with 
L-glutamine (Life Technologies),supplemented with 
10% fetal bovine serum (Gibco, AUS); penicillin (1000 
U/mL) and streptomycin (1000 ug/L) (Gibco BRL, 
AUS).Cells were grown till they reached 100 % 
confluency at 370C5%CO2, In humidified conditions. 
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Media was replaced every 2 days. Cells were then 
harvested by 0.25% TrypLe express (Life 
Technologies, AUS) and detached cells were washed 
twice in cell culture media and cell number and 
viability assessed by Countess® cell counter (Life 
Technologies, AUS).  
ERS 
Tunicamycin (TUN) was procured from Sigma, 
AUS in a solution form (DMSO solution) at a 
concentration of 5mg/mL. The concentration was 
finalized to 10µg/mL before adding to the cells. 
RNA Extraction and cDNA synthesis 
RNA was extracted from LS174T cells with a cell 
population of 3x105using RNeasy Mini Kits (Qiagen, 
AUS) with gDNA removed using the RNase-Free 
DNase set (Qiagen, AUS). RNA (quantitative and 
qualitative) analysis was performed using an 
Experion automated electrophoresis system (Bio-Rad 
Laboratories, AUS) and RNA samples with an 
RQI > 7.0 were considered suitable for expression 
analysis. An iScript cDNA synthesis kit (Bio-Rad 
Laboratories, AUS) was used to transcribe one 
microgram of total RNA to cDNA as per the 
manufacturer’s protocol.  
RT-PCR 
The RT-PCR was performed using Taqman ® 
probes (Life Technologies, AUS) for GAPDH (Hs039 
29097_gl), ATF6 (Hs00232586_m1), XBP1 (Hs00231936 
_m1), GRP78 (Hs0060719_gH), CHOP (Hs00358796_ 
g1), NLRP3 (Hs00918082_m1), IL1β (Hs01555410_m1) 
and PERK (Hs00984006_m1). The RT-reaction mixture 
consisted of 40ng of cDNA, Taqman Fast Advanced 
Master mix (Life Technologies, AUS), 1µL of gene 
specific probe/ total volume of 20µL. The reactions 
were run in duplicate on an RT-PCR machine 
(StepOne Plus-Life Technologies).Thermo cycling 
conditions included: 90oC for 20s, 40 cycles at 95oC for 
1 s and 60oC for 20s. Gene expression was quantified 
using the comparative (ΔΔCT) method where the 
threshold cycle (CT) for each gene was normalized to 
reference gene GAPDH. 
Cytokine quantification by Bio-Plex 
LS174T cells were used for the quantification of 
IL-8, IL-4, TNF-α and IL-10 cytokine levels. Cells were 
subjected to the respective treatments (tunicamycin 
and bilirubin) and were cultured in 12-well culture 
plates (Greiner, AUS). Wells were seeded at a density 
of 3.0 × 105 cells in 2.0 mL of medium and incubated 
overnight at 37oC/5% CO2 to allow the cells to adhere. 
Medium was replaced the next day Tunicamycin 
(10µg/mL in DMSO) and 4PBA (40µg/mL) were 
incubated for 6 hours at 37oC/5% CO2. The treatment 
groups then consisted of: no-treatment (LS174T cells 
with media), tunicamycin only, tunicamycin+ UCB 
10µM and UCB 10µM only. After 6 hr of treatment, 
the media from each well was collected and used for 
quantification of cytokines using Bio-Plex® Pro 
human cytokine assay kits (Bio-Rad®), according to 
the manufacturer’s protocol. Briefly, 50 µL of cytokine 
beads were added to the 96-well plate and incubated 
for 30 min before washing twice with wash buffer. 
Then, 50 µL of each standard, blank and samples were 
added to the respective wells and incubated at room 
temperature on a shaker at 850 rpm for 30 min. After 
incubation, the wells were washed thrice and 25 µL of 
detection antibody was added to each well and 
incubated at room temperature on a shaker at 850 rpm 
for 30 min. Later, 50 µL of streptavidin-PE was added 
to each well and incubated at room temperature in a 
shaker at 850 rpm for 10 min. After three washes, 125 
μL assay buffer was added to each well and incubated 
at room temperature for 30 sec. After incubation, the 
plates were read on the Bio-Plex® 200 system and data 
was analyzed in Bio-Plex Data ProTM Software. All 
the experiments were performed in triplicate.  
Apoptosis assays 
Caspase- 3 assay 
The caspase-3 fluorometric assay was performed 
on cell lysates which were collected after the 6 hour 
treatment according to assay kit instructions and 
published research protocols [23]. This enzyme assay 
works based upon the hydrolysis of the caspase-3 
peptide substrate (acetyl-Asp-Glu-Val-Asp or AC- 
DEVD) conjugated to a fluorochrome at the 
C-terminal Asp, resulting in the release of the 
fluorescent moiety. After the fluorometric treatment, 
the fluorescence (absolute units) was measured using 
the CytoFluor Multi-Well Plate Reader Series 4000 
spectro-fluorometer from PerSeptive Biosystems 
(Framingham, MA, USA). 
Annexin V assay 
The Annexin-V-Fluos assay (cat. no. 118286810 
01, Roche Diagnostics, Zug Switzerland) was utilized 
to measure apoptotic (annexin V) cell populations. 
After the 6 hour treatment cells were incubated in 
incubation buffer ((10 mM HEPES at pH 7.4, 140 
mMNaCL, 2.5 mM CaCl2) supplemented with 
annexin V–PI mix for 15 min at RT and the cells were 
analyzed by confocal microscopy with DAPI for 
nuclear staining and FITC channel (fluorescein) for 
visualizing apoptotic cells (Nikon AR1MP) [24]. 
Toxicity Assay Lactate Dehydrogenase (LDH) 
After incubation with the respective treatments, 
the supernatants were collected for the determination 
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of cytotoxicity by using the lactate dehydrogenase 
(LDH) assay. The cellular cytotoxicity was assessed by 
the LDH in-vitro cytotoxicity assay (TOX7, Sigma- 
Aldrich, St. Louis, MO, USA). The culture supernat-
ants were centrifuged at 250×g for 4 min. An aliquot 
containing 50 µL of either blank (complete medium) 
or control (cells only) and cells with DMSO 
supernatants (various concentrations obtained after 
the respective time point incubations was mixed with 
100 µL of a solution containing the LDH assay mixture 
(LDH substrate, LDH dye, and LDH cofactor). The 
mixture was then incubated at room temperature for 
20 to 30 min and the reaction was quenched by the 
addition of 1N hydrochloric acid (15 μL). The 
absorbance was measured spectro-photo-metrically 
by using a plate reader (Spectra Max M2 microplate 
reader, Sunnyvale, CA, USA) at a wavelength of 490 
nm. The cellular viability was examined by a Trypan 
Blue exclusion staining assay using a Countess 
Automated Cell Counter (Thermo-Fisher, Waltham, 
MA, USA). 
Western blot of PARP assay 
Total cell protein was extracted from 1 × 106 
treated (6 hrs) LS174T cells by firstly washing the cells 
with HBSS followed by homogenization in 2 mL of 
RIPA buffer/10% of protease inhibitor (Sigma- 
Aldrich, AUS). Cell supernatant was generated by 
centrifugation at 12000 rpm for 20 min at 4 °C. Thirty 
micrograms of protein from each sample was 
denatured in Laemmli loading buffer (Bio-Rad 
Laboratories, AUS; 1:1 v/v) and separated on precast 
12% SDS-PAGE gels (Bio-Rad Laboratories, AUS) 
followed by overnight transfer onto PVDF membr-
anes (Millipore, AUS) at 30 mV at 4 °C. The blot was 
blocked with 5% non-fat milk, before being incubated 
with anti-GADPH (#14C10, 1:3000, Novus Biologicals, 
AUS), poly(ADP-ribose)polymerase (PARP), cleaved 
PARP (Sigma-Aldrich, Australia) overnight at 4 °C in 
blocking buffer. The blot was washed in Phosphate- 
buffered saline (PBST) and incubated with appropr-
iate species monoclonal horseradish peroxidase- 
conjugated anti-IgG secondary antibodies (1:5000) for 
1 h at 20 °C. Bands were visualized using Supersignal 
West Pico chemiluminesce kit (Thermo Scientific, 
AUS), digitized and band intensities determined 
using a Fuji LAS-3000 Imager (Fuji Life Sciences, 
Japan). Samples from all groups were included in 
individual blots to ensure accurate quantification 
across multiple blots. 
Proliferation assay 
The proliferation assay 5-ethynyl-2′-deoxyuri-
dine (EdU)) Invitrogen, Australia) was performed as 
per manufacturer instruction and published protocols 
[25].In brief, Click-iT™ EdU Flow Cytometry Assay 
Kit, Invitrogen™ was added at a 50 μM final 
concentration. For the Click reaction, cells were 
collected into 3 ml of PBS containing 1% BSA, 
centrifuged and fixed with 100 μl of 4% para 
formaldehyde for 15 min. Cells were visualized using 
confocal microscopy (Nikon AR1MP) with DAPI as 
nuclear staining. 
Statistical analysis 
Statistical significance of the differences between 
groups among repeated experiments was determined 
by one-y and two way ANOVA and Fisher's LSD-tests 
using GraphPad Prism 4 software (GraphPad 
Software Ltd, La Jolla, CA, USA). The results are 
expressed as the mean values ± standard deviation. In 
all statistical tests, a P-value <0.05 was considered 
statistically significant. 
Results 
Effect of DMSO on LS174T cells 
Initially to assess the toxic effects of DMSO (if 
any exists) against the LS174T cells, we have carried a 
LDH assay to verify any cell death due to toxicity. 
Compared to the cells alone group which has shown 
99 % viability, 0.1%, 0.3% and 0.5% concentrations 
have shown a very minimal toxicity. 1% DMSO has 
exhibited about 80% toxicity. We have for this reason 
employed 0.5 % DMSO in our cell culture media 
either to dissolve TUN or UCB in our study. 
 
 
Figure 1. Toxicity effects of DMSO on LS174T cells. Data represented in the above 
figure demonstrates cells alone (without DMSO) and cells in media with DMSO 
concentrations 0.1 %, 0.3 %, 0.5 % and 1%) Data are shown as the mean fold 
change ± SEM (vs. vehicle: *, p < 0.05) 
 
UCBreduces ER stress in LS174T colon cancer 
cells 
First of all, we investigated the efficacy of UCB in 
attenuating ER stress in LS174T cells. The addition of 
tunicamycin 10µg/mL for six hours was used to 
increase mRNA expression of all the ER stress and 
inflammatory markers (Figure 2), namely Grp78 
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(29.8±2.0 fold; p<0.05), NLRP3 (2.5±0.15 fold; p<0.05), 
IL1-β (1.04±0.5 fold, p<0.05), XBP1 (24.5±2.0 fold; 
p<0.05), PERK (24.5±2.0 fold; p<0.05) and ATF6 
(22.4±1.2 fold; p<0.05) (mean ± SEM; n=3) 
corresponding to ER stress induction. Co-treatment 
with UCB for six hours significantly reduced ER stress 
marker mRNA expression. The mRNA expression 
levels of the UCB alone and UCB+tunicamycin groups 
were as follows: Grp78 (UCB alone (1.13±3.0) UCB+ 
tunicamycin 10µM (18.2±2.0), where there was a 
surprising marked decrease in the ER stress markers; 
NLRP3 (UCB alone (1.5±0.4) UCB+tunicamycin (0.9± 
0.3) UCB+tunicamycin 10µM (0.56±0.9); IL1-β (UCB 
alone (no difference) UCB+tunicamycin (0.50±0.08) 
UCB+tunicamycin (0.32±0.07); XBP1 (UCBalone (1.6± 
0.10) UCB+tunicamycin 0.1mM (1.15±0.05) UCB+tun-
icamycin 1mM (0.035±0.02) UCB+tunicamycin 10mM 
(0.92±0.03). All the bilirubin treatments exhibited sig-
nificance, with PERK (UCB alone (1.21±0.4) UCB+ 
tunicamycin 0.1 mM (1.16±0.07) UCB+tunicamycin 
1mM (1.05±0.05) UCB+tunicamycin 10mM (1.0±0.01), 
and ATF6 (bilirubin alone (1.58±0.14) UCB+tunica-
mycin 0.1mM (1.04±0.015) UCB+tuncamycin 1mM 
(1.0±0.01) UCB+tunicamycin 10mM (0.90±0.02) (P< 
0.05).  
UCB ameliorates tunicamycin-mediated 
inflammatory responses 
When LS174T cells were treated with tunicamy-
cin, media IL-8, IL-4 and TNFα concentrations 
increased to 1258±90, 1997±13 and 2.9±0.1 pg/mL 
respectively (Figure 3). During co-treatment with 
UCB 10µMalone and UCB 10µM+tunicamycin, 
concentrations of IL-8, IL-4 and TNFα decreased 
significantly (p<0.05) compared to the tunicamycin 
group. For the IL-8 group, the levels were 
downregulated by 587.51±3.39 pg/mL for bilirubin 
10mM and 910.273± 29.85 pg/mL for bilirubin 
10mM+tunicamycin 10µg/ mL. IL-4 levels were down 
to 585.85±4.33 pg/mL for bilirubin 10mM and 
1258.39±8.6pg/mL for bilirubin 10µM+tunicamycin 
10µg/mL. TNFα was reduced to 2.20±0.1 pg/mL for 
bilirubin 10mM and 1.89±0.11 pg/mL for bilirubin 
10mM+tunicamycin 10µg/mL. IL-10 concentrations 
increased from 3.0±0.10 pg/mL to 7.40±0.71 pg/mL 
for UCB 10µM+tunicamycin 10µg/mL. 
Bilirubin increases apoptosis in the LS174T 
cancer cell line 
To verify the induction of apoptosis, cells after 
treatments were stained with Annexin V (FITC) 
(Figure 4). Greater apoptosis occurred in cells treated 
with UCB (10µM) (Figure 4d) alone compared to the 
UCB (10µM) and tunicamycin treated group (Figure 
4b). The control group cells that were treated with the 
solvent control only did not show increased Annexin 
V positive staining. Cells treated with UCB alone 
(10µM) also demonstrated a change in their 
morphology such as condensed nucleus and 
accumulation of Annexin V in cytoplasm, suggesting 
enhanced permeability when compared to the solvent 
control group and tunicamycin group shown under 
higher magnification (Figure 4e). 
 
 
 
Figure 2. mRNA expression of ER stress markers [relative mRNA expression levels are vs. control and normalized to GAPDH (n = 3). Data are shown as the mean fold 
change ± SEM (vs. vehicle: *, **, ***; p < 0.05]. 
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Figure 3. Cytokine concentrations in the media of LS174T cell line supernatant. Groups designated with different letters are significantly different (p < 0.05) *. 
 
Figure 4. Annexin V assay on LS174T cell line. a. Solvent control; b. TUN+UCB; c.TUN; d. UCB (10µM) alone; e. High magnification of UCB 10µM alone depicting disoriented 
nucleus. Annexin staining is denoted by green fluorescence and DAPI (nuclear staining) by blue fluorescence. Scale bar represents 200µm 
 
For investigating PARP activity, protein from the 
cells (LS174T) was obtained after treatment and 
processed for protein expression (Figure 5). Cleaved 
PARP, which is a caspase substrate activator, was 
detected in the UCB-treated groups, suggesting that 
UCB initiated apoptosis. These results were 
supported by Caspase 3 analysis, which showed a 
significant increase in Caspase 3 expression in the 
UCB alone group compared to tunicamycin and 
tunicamycin+UCB. 
Bilirubin reduces ERS mediated cellular 
proliferation 
Considering the results of the apoptosis assay, 
we then sought to determine whether differences in 
cellular viability would influence proliferation. The 
EdU assay for in vitro proliferation was applied and 
assessed through DNA-synthesis and detected the 
Int. J. Med. Sci. 2019, Vol. 16 
 
http://www.medsci.org 
141 
incorporation of the alkyne-modified nucleoside EdU 
(5-Ethynyl-2′-deoxyuridine) into DNA using copper- 
catalysed azide-alkyne click chemistry to attach 
fluorescent probes. We have here included only the 
highest concentration of bilirubin (10µM) as it was the 
most significant dose observed in the previous assays. 
The results indicated reduced cell proliferation was 
highest in the TUN group (Figure 6b) showing that 
ERS induction in a cancer cell line leads to increased 
proliferation. The proliferation was reduced in UCB+ 
TUN treated groups, compared to the TUN only 
group and the cells alone (Figure 6a). The lowest 
proliferation was observed in the UCB alone treated 
group (Figure 6d). The proliferation rate was 
quantified in Figure 6e. 
 
 
Figure 5. Quantification of PARP and Caspase 3 expression. a.Western blot of PARP cleavage of LS174T cells treated with TUN and UCB (0.1, 1 and 10 µM) b. PARP cleavage 
quantification c. Caspase 3/7 fluoremetric assay 
 
Figure 6. Proliferation assay of LS174T cells. a) Cells alone; b) Proliferation in cells with TUN treatment; c) TUN+UCB; d) UCB only e) Quantification of proliferation by Image 
J®. Scale bar represents 100µm. 
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Discussion 
In the present study, we have shown that a 
co-treatment with UCB reduces the mRNA expression 
of ERS and inflammation induced by TUN, increases 
apoptosis and reduces cellular proliferation in the 
tumour-derived LS174T cell line. These data are novel 
and suggest that bile pigments present in the gut may 
inhibit inflammation in the gut and related effects. 
The concentrations tested can also be correlated with 
clinical conditions of Gilbert’s syndrome (GS). The 
serum bilirubin concentration in GS ranges between 
20 and 50 µM [26], and approximates a bilirubin: 
albumin ratio of 0.04–0.1. The 1µM dose (bilirubin: 
albumin 0.032) in this study therefore most closely 
replicates the bilirubin:albumin ratio in GS. 
The crucial role of the unfolded protein response 
(UPR) in numerous cancers and cancer development 
is well accepted and documented [27]. The UPR, 
which is a key player in the signalling of ERS, has 
various effectors including XBP1, PERK and ATF6 
which are increased in many neoplasms including 
brain and pancreatic lesions. Furthermore, Grp78 is 
over-expressed in a number of cancer cell lines. The 
UPR is also linked to the presence of cell dormancy, 
secretory switch mechanisms, epithelial -to-mesench-
ymal transition (EMT), tumour angiogenesis and 
tumour autophagy which are associated with ATF6, 
PERK and IRE1 activation. These phenomena are 
characteristic of the role of ERS in colitis and colon 
cancer. XBP1 has been correlated to hypoxia inducible 
factor-1α activation thereby facilitating tumour survi-
val, activating SNAIL (snail-related protein) thereby 
promoting metastasis via EMT and glucose uptake 
[28]. Moreover, long-standing ERS activation is 
related to metastasis and drug resistance and thus 
targeting ATF6, PERK and other ER stress responses 
holds potential for anti-cancer therapy [29]. We 
employed a similar strategy in this study whereby we 
initially showed that UCB inhibits tunicamycin- 
induced ER stress in LS174T cells. Bilirubin at a dose 
of 10µM reduced the expression of UPR genes Grp78, 
XBP1, PERK, ATF6 and inflammatory mediators such 
asNLRP3 and IL-1β. Previous effective therapeutic 
strategies are also harnessed by bitter melon extracts 
against ER stress in the treatment of tunicamycin- 
induced ERS [30]. 
With the present experiment results, we aimed to 
demonstrate the link between ER stress and inflam-
mation induced by TUN by assessing concentrations 
of pro- and anti-inflammatory cytokines after six 
hours of co-incubation. The activation of pathways 
within UPR is interconnected to inflammation 
through mechanisms including ROS, calcium release 
from ER and the acute phase response [31]. For 
example, interleukin-8 (IL-8) may exert tumourigenic 
effects demonstrated in IL-8 silencing studies which 
reversed the tumour-like characteristics and drug 
resistance of HCT116 and Caco2 cells [32]. Bilirubin 
alone (10µM) significantly decreased the concentra-
tion of IL-8 and furthermore demonstrated similar 
effects in combination with tunicamycin. Targeting 
IL-8 and its receptor CXCR2 represents a strategic 
mechanism for targeting cancers and also chemosen-
sitising tumours [33]. In the colon, IL-8 transfectants 
demonstrate increased proliferation and cell 
migration with its silencing reversing the effect [32]. 
Many of the pro-inflammatory cytokines are implica-
ted in the intestinal microenvironment, including 
IL-4. IL-4 induces colitis and its over-expression 
induces acute and fatal colitis [34]. Self-renewing 
cancers formed from stem cells (CSC) can be resistant 
to chemical therapies. Blockade of IL-4 leads to 
initiation of apoptotic signalling in CSCs, suggesting 
that IL-4 could be used as one of the many potential 
therapeutic targets [35]. Bilirubin at a dose of 10µM 
decreased IL-4 concentrations in the conditioned 
media of LS174T cells when compared to the TUN 
treatment. Furthermore, IL-4 expression was accomp-
anied by increased TNF-α expression, suggesting its 
active role in intestinal diseases and cancer [34, 36]. 
TNF-α alone could be used as a diagnostic marker for 
colorectal cancer and represents a promising 
therapeutic target [37]. Similar to IL-4, UCB reduced 
TNF-α secretion compared to the TUN group, where 
it was increased due to ER stress. These conclusions 
are supported by a study by Zins et al. where the 
human TNF-alpha gene silencing decreased mouse 
macrophage TNF-alpha, CSF-1, MMP-2, and VEGF-A 
mRNA expression when co-cultured with human 
cancer cells [38]. As much as reducing pro-inflamma-
tory cytokines concentrations are important, it is also 
important to increase the anti-inflammatory cytokines 
in order to counter-regulate inflammatory responses. 
In the in vivo models, oral administration of IL-10 
microparticles decreased polyposis in the ApcMin/+ 
model by suppressing the development of 
IL-17-producing Tregcells and inducing conventional, 
IL-17-negative Treg cells [39]. This finding helps to 
explain the therapeutic nature and role of IL-10 in 
colon cancer. IL-10 demonstrates immune-suppre-
ssant effects in cancer [40]. Our study could 
emphasise the potency of bilirubin in increasing the 
anti-inflammatory cytokine IL-10 in LS174T cells in 
accordance with a previous study where 
IL-10-deficient mice demonstrated increased 
pro-inflammatory cytokine production. In these mice, 
IL-10 treatment improved intestinal inflammation and 
aided in ameliorating disease progression [41].  
Induction of apoptosis via activation of caspases 
is a critical feature associated with the effectiveness of 
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potential cancer treatments [42, 43] including the use 
of tetrapyrrolic bile pigments in human cancer cells 
[44]. Apart from being used as a novel biomarker for 
nasopharyngeal carcinoma [45], UCB has the potential 
to cause cell cycle arrest at G0/G1 and exert 
pro-oxidant effects at high concentrations [46]. 
Human biliverdin reductase, which chemically 
reduces biliverdin to bilirubin, was recently 
implicated as a regulator in cancer development and 
maybe useful in designing biomarkers for cancer 
patients [47]. A similar study reported that lower 
serum bilirubin levels occur in colorectal cancer 
patients with a 1µM decrease in serum bilirubin 
related to a 7% rise in CRC risk [48]. Bilirubin 
possessed anti-tumour properties in vitro in HRT-18 
cell lines and also BALB/c nude mice bearing HRT-18 
colon cancer xenografts where it has shown that 
bilirubin defended against cancer by interfering with 
pro-carcinogenic pathways [49]. Bilirubin may also 
demonstrate synergistic anti-cancer effects inducing 
apoptosis in HeLa cells [50]. It was, however, 
necessary to consider the mode of cell death and 
determine whether bilirubin induced intrinsic cell 
death, and therefore we demonstrated that bilirubin 
induced apoptosis via PARP and Caspase 3. Caspase 
3 and PARP are regarded as downstream activators of 
Caspase 9 [51], which may suggest the initiation of 
mitochondrial-dependent intrinsic cell death similar 
to previous studies showing D-limonene induced 
programmed cell death [51]. We support this 
conclusion by demonstrating increased AnnexinV 
staining to show that bilirubin initiates early 
apoptosis in LS174T cells. Annexin V is a 35–36 
kDaCa2+-dependent phospholipid-binding protein 
with high affinity for PS, and binds to exposed 
apoptotic cell surface phospholipid phosphatidylser-
ine [52, 53]. Our results clearly show the early cell 
death recorded in cells treated with 10µM bilirubin 
compared to that of the TUN group which evidently 
supports a conclusion that bilirubin exerts 
pro-apoptotic effects in cancer cell lines. 
In parallel to the apoptosis assay, we assessed 
the proliferation rate via the EdU click non- 
radioactive method [54] which showed reduced 
proliferation in the bilirubin 10 µM group compared 
to the TUN group. In previous studies, bilirubin and 
biliverdin inhibited smooth muscle cell proliferation 
at the G1 phase and also phosphorylation of the 
retinoblastoma tumour suppressor protein inhibition 
in primary rat and mouse vascular smooth muscle 
cells (VSMCs) [55]. We have performed the in vitro 
proliferation assay in congruence with these results 
supporting the cell proliferation arresting ability of 
bilirubin in LS174T cells.  
Conclusions 
In conclusion, bilirubin despite of reducing ERS 
and ERS mediated inflammation, also increases 
cancer cell apoptosis and reduces proliferation. These 
data add further weight to the possibility that 
bilirubin can be used as a potential anti-inflammatory 
and anti-cancer agent in the colon. In the future we 
intend to translate this study to in-vivo and use 
unconjugated bilirubin as therapeutic agent in 
reducing the inflammatory mediated negative effects 
in a mouse carcinogenic model and assess the 
downstream effects. 
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